In this article, IBO updates the patent litigation landscape for the analytical instrument and lab product industry. New Development In March, the US Court of Appeals for the Federal Circuit reversed in part and vacated in part the judgment in favor of Enzo Biochem and Yale University in their patent infringement suit against Life Technologies […]
US equity markets traded at record levels in April due to stronger-than-expected corporate earnings and additional monetary policy easing in China. However, weak US manufacturing, durable goods orders and GDP data caused equity markets to retract toward the end of the month. US economic growth nearly stalled in the first quarter, expanding at a modest […]
This year, the first edition of IBO’s biannual article on new labs reports the construction of several academic, government and industrial labs. The table on page 3 shows some of the largest buildings for academic research in the sciences that have been approved or are already under construction, as well as new labs in the […]
The annual American Association of Cancer Research meeting (AACR) was held April 18–22 in Philadelphia, Pennsylvania. Attendance for the conference was 19,300, up about 4% from last year (see IBO 4/30/14). The number of companies exhibiting totaled 438. A notable trend in the exhibit hall was the number of CRISPR/Cas9 products and services available from […]
Fiscal first quarter sales ending December 31, 2014, for Brooks Automation Life Science Systems (LSS) grew 36.8%, 7.3% excluding the acquisition of FluidX (see IBO 10/15/14), to $16.7 million (see page 12) to account for 14% of company sales. Product revenue grew 56.9%, 12.7% excluding the acquisition, to account for 77% of LSS revenue. LSS […]
Fourth quarter 2014 IBO Lab Equipment/Consumables Sales Index revenues grew 4.6%, 6.3% excluding currency, to $4,679 million. Growth was driven by strong results for Thermo Fisher Scientific Laboratory Products and Services (LPS). Index adjusted operating profit improved only 0.3% to $811 million. Operating margin declined 70 basis points to 15.7% of sales due to divestments, […]
Cannabis testing in the US has made progress on multiple fronts but still has a long way to go, resulting in new opportunities for lab product and instrumentation companies. Testing demand is growing as more states legalize recreational use, and institute testing and lab requirements. But the fragmented market and unique business environment creates challenges […]
With the completed acquisition of Life Technologies (see IBO 2/15/14) in 2014, Thermo Fisher Scientific further solidified its number one position among IBO’s list of the top 30 analytical and life science instrument, aftermarket and lab product companies. All sales and sales growth figures in this article are based on IBO’s calculations of companies’ revenues […]
Financials for the IBO Laboratory Sales Index have been updated from the February 15 issue to include all the companies. Fourth quarter 2014 Laboratory Sales Index sales grew 3.8%, 6.1% organically, to $7,287 million. Operating profit climbed 7.7% to $1,748 million, and operating margin advanced 220 basis points to 21.3% of sales. For 2014, Index […]
In March, the US Office of Science and Technology Policy (OSTP) issued a report on the budget authority for federal R&D-facilities construction and major capital equipment (R&D infrastructure) in President Obama’s fiscal year 2016 (FY16) budget. The report included actual FY14 and estimated FY15 budget authorities for R&D infrastructure, which is defined as support for […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
